Örn Almarsson
CEO
Axelyf
Axelyf develops next-generation lipid nanoparticle (LNP) delivery systems to advance RNA therapeutics. The company integrates proprietary AXL LNPs with AI-informed approaches for enhanced extrahepatic delivery. This focus aims to unlock the full therapeutic potential of nucleic acid medicines.
- Artificial Intelligence
- Biotechnology
Updated 6 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Many promising small molecule drugs derived from natural sources are not well absorbed by the body due to chemical instability and poor water solubility, limiting their therapeutic potential. Current delivery methods for mRNA-based therapies also face challenges in achieving effective, targeted, and safe delivery to specific tissues.
Solution
Axelyf is developing optimized delivery systems for small molecule drugs and mRNA-based therapies, focusing on inflammatory and autoimmune conditions. For small molecules, they create chemically stable prodrugs with high oral bioavailability and favorable distribution properties. For mRNA therapies, Axelyf utilizes AI-powered lipid nanoparticle (LNP) design to create more effective and precisely targeted RNA delivery systems. Their lead candidate, an orally administered astaxanthin prodrug, is entering clinical trials for treating inflammation.
Target Audience
Axelyf's primary target audience includes patients with inflammatory and autoimmune diseases, as well as pharmaceutical companies seeking advanced drug delivery technologies for their therapeutic candidates.
Features
- Development of oral prodrugs from natural lipids with improved bioavailability and stability
- AI-powered LNP design for targeted delivery of RNA therapeutics
- Molecular library of potent delivery compounds for mRNA
- Focus on inflammatory and autoimmune disease areas
- BPH-555: Clinical candidate (astaxanthin prodrug) for inflammation and autoimmune indications
- Supramolecular chemistry approach for nanoparticle design